Coeptis Aims to Bring AI Innovation in Biotechnology and Technology
WEXFORD, Pa., Dec. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company specializing in innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, proudly announces the completion of its acquisition of the NexGenAI Affiliates Network platform alongside the official launch of Coeptis Technologies. This new division is strategically aimed at diversifying the company's growth potential.
The acquisition of the NexGenAI Affiliates Network platform, which was developed by NexGenAI Solutions Group, Inc. and its affiliates ("NexGenAI"), offers what Coeptis views as groundbreaking AI-powered marketing software and advanced robotic process automation (RPA) capabilities. This transformative AI-powered tool is designed to empower marketers to process vast amounts of data, optimize campaigns, enhance customer engagement, and streamline operations-crucial elements in the highly regulated sectors of biotech, pharmaceutical, and multi-level marketing (MLM) industries.
Dave Mehalick, President and CEO of Coeptis Therapeutics, stated, "We are excited to integrate the NexGenAI Affiliates Network platform and its AI and RPA-driven tools into our offerings. In industries like biotech, pharma, and MLM, where competition is so high and regulatory challenges are complex, having advanced tools to optimize marketing, streamline operations, and drive measurable results is critical."
Anshuman Dash, Lead Advisory behind the development of the NexGenAI Affiliates Network platform, commented, "The integration of NexGenAI's innovative AI-powered marketing solutions with Coeptis Therapeutics' forward-thinking approach marks a transformative step forward. This acquisition aligns nicely with Coeptis' mission to drive innovation in highly regulated industries, revolutionize marketing strategies and operational efficiencies and ultimately deliver greater value to the partners and the industries served."
This acquisition reflects Coeptis' commitment to leveraging advanced technologies to enhance its capabilities and drive innovation within the biopharmaceutical sector. By incorporating NexGenAI's AI-powered marketing solutions, Coeptis aims to provide state-of-the-art tools to companies seeking to overcome marketing challenges in competitive and highly regulated industries.
Dave Mehalick elaborated further on the NexGenAI Affiliates Network platform acquisition, stating, "In highly competitive industries such as biotech, pharma, and MLM, having advanced tools to optimize marketing, streamline operations, and drive measurable results is not just beneficial-it's essential for our success."
About Coeptis Therapeutics Holdings, Inc.:
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institute. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com
About NexGenAI:
NexGenAI Holding Group Inc., along with its majority-owned subsidiary NexGenAI Solutions Group, Inc., has developed a proprietary suite of advanced tools that power the NexGenAI Affiliates Network platform. These tools, featuring AI-driven marketing software and robotic process automation capabilities, are designed to optimize campaigns, streamline operations, and provide actionable, data-driven insights. NexGenAI's platform provides cutting-edge AI-driven solutions that revolutionize business operations across various sectors. By leveraging artificial intelligence, NexGenAI empowers companies to automate processes, optimize efficiency, and drive sustainable growth. For more information on NexGenAI, visit nexgenai.io.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
[email protected]
SOURCE Coeptis Therapeutics, Inc.
